NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives $14.00 Consensus Target Price from Analysts

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $14.00.

NRSN has been the subject of a number of analyst reports. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a report on Monday, December 22nd. Zacks Research raised NeuroSense Therapeutics to a “hold” rating in a research note on Wednesday, October 15th. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Noble Financial raised shares of NeuroSense Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Monday.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Squarepoint Ops LLC lifted its position in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the second quarter worth approximately $54,000. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Price Performance

NRSN stock opened at $0.78 on Wednesday. NeuroSense Therapeutics has a 52-week low of $0.68 and a 52-week high of $2.60. The company’s 50-day simple moving average is $0.98 and its 200-day simple moving average is $1.32.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.